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While there is a high interest in drug combinations in cancer therapy, openly accessible datasets 
for drug combination responses are sparse. Here we present a dataset comprising 171 pairwise 
combinations of 19 individual drugs targeting signal transduction mechanisms across eight cancer 
cell lines, where the effect of each drug and drug combination is reported as cell viability assessed by 
metabolic activity. Drugs are chosen by their capacity to specifically interfere with well-known signal 
transduction mechanisms. Signalling processes targeted by the drugs include PI3K/AKT, NFkB, JAK/
STAT, CTNNB1/TCF, and MAPK pathways. Drug combinations are classified as synergistic based on the 
Bliss independence synergy metrics. The data identifies combinations that synergistically reduce cancer 
cell viability and that can be of interest for further pre-clinical investigations.
Background & Summary
Treatment of non-resectable cancer has previously mainly relied on cytotoxic chemotherapy that indiscriminately 
kills all rapidly dividing cells. With the discovery of molecular mechanisms driving cancer, a new generation 
of molecularly targeted drugs has entered the market over the last two decades. A remaining challenge in the 
envisaged transition from ‘one-size-fits all’ therapeutic approach to personalised treatment is the development of 
resistance to single-targeted drug treatment. Combinatorial therapy may be able to overcome this by co-targeting 
multiple mechanisms involved in cancer cell growth and survival1,2.
Already compelling results have been achieved with some combinations of cancer signalling inhibitors, e.g. 
the synergistic combination of MAP2K1/2 (MEK) and BRAF inhibitors for malignant melanoma3–5 and lung 
adenocarcinoma6. This has sparked a wide interest in identifying novel efficient pairs of small molecule targeted 
drugs. However, our knowledge about beneficial targeted drug combinations is still limited, partly due to the 
combinatorial complexity.
Few high-throughput screens testing multiple targeted drugs in combinations have been published with open 
access data. Examples include combinatorial screens on ovarian cancer cell lines7, melanoma cell lines8, sarcoma 
cell lines9 and lung-cancer-patient-derived cell culture models10. In a study performed by O’Neil et al., combi-
nations of around 12 targeted drugs were screened across a panel of 39 cancer cell lines. In total 22 experimental 
drugs were tested in all possible combinations and in combination with 16 approved drugs11. The National Cancer 
Institute (NCI) screened pairs of 104 FDA-approved cancer drugs against the NCI-60 cell line panel. Around 30 
of the tested compounds can be classified as small molecule targeted therapies12. In the AstraZeneca’s drug com-
bination data set of the latest DREAM challenge, 118 drugs, including 59 targeted therapies, were tested in 910 
pairwise combinations against 85 cancer cell lines13.
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In this paper, we report results from a high-throughput screen testing the effects of combining 19 
small-molecule inhibitors on cancer cell viability. The drugs target signalling proteins involved in several well 
described signalling pathways, including PI3K/AKT, NFkB, JAK/STAT, CTNNB1/TCF, and MAPK pathways. 
Inhibitors were selected for high specificity and a minimum of known off-target activities, as judged from char-
acterizations available from the MRC PPU lab (https://www.ppu.mrc.ac.uk/)14 for 15 of 19 drugs. Eight cancer 
cell lines were treated with single inhibitors and 171 pairwise combinations at equimolar concentrations from 
10–0.16 µM. Cell viability was determined after 48 hours from ATP content using CellTiter-Glo 2.0 (Promega). 
Several of the synergistic combinations involved the PI-103 inhibitor. Six of these combinations were investigated 
in a secondary screen. We here applied a matrix design allowing for synergy assessment outside the equimolar 
range and determined inhibitor effects from both viability (ATP content) and cell confluency (brightfield imag-
ing). Figure 1 gives a schematic overview of the study design.
In the here presented dataset we rediscovered previously reported synergistic combinations and discovered 
several new synergies. The synergistic reduction of cell viability resulting from jointly targeting PI3K/mTOR and 
TAK1, previously reported by us for the AGS cell line15 and later by others16, is observed in two of the tested cell 
lines. Furthermore, we rediscovered the synergistic effect of jointly targeting MEK and PI3K17–19. Recently, Sathe 
et al. have reported on increased effect of combined inhibition of PI3K/mTOR and PDPK1 in bladder carcinoma 
cells20. We identify that combined targeting of PI3K/mTOR and PDPK1 is potent across multiple cancer cell 
lines. The PI3 kinase is one of the canonical activators of PDPK1, and our dataset thus identifies this ‘vertical 
synergy’ intervention by targeting multiple points in one cascade as a potential chemical intervention for inhib-
iting PI3K-dependent cancer growth across cell line models representing different tissue types. Co-targeting of 
multiple vertical points in one cascade is also the rationale for the clinically verified ‘vertical synergy’ observed by 
jointly targeting MEK and BRAF3–6. Moreover, PI3K and PI3K/mTOR inhibitors tested in a clinical setting (e.g. 
pictilisib21 and apitolisib22) have suffered from toxic effects23,24. Thus, identification of compounds that increase 
the therapeutic index for PI3K inhibitors could enable new uses for PI3K inhibition in oncology.
The outcomes of our work contribute to expanding the available data sets on novel combinations of targeted 
drugs across a variety of cancer cell lines and can benefit the fields of cancer therapeutics, molecular signalling 
interventions and molecular cancer biology.
Methods
Cell lines and culturing. The following eight cancer cell lines were used in this study: A498 (kidney can-
cer), AGS (gastric adenocarcinoma), COLO 205 (colorectal cancer), DU-145 (prostate cancer), MDA-MB-468 
(breast cancer), SF-295 (glioblastoma), SW-620 (colorectal cancer), and UACC-62 (melanoma). All cell lines 
used in the study are of human origin. Seven of the cell lines were obtained from the NCI-DCTD Repository, 
Frederick MD, and are part of the DTP 60 cell line panel (NCI-60 collection). The AGS cell line was obtained 
from ATCC. AGS cells were cultured in HAMS’s F12 (GIBCO, 21765-029) supplemented with 10% FBS (GIBCO, 
10270-106), 10 µg/ml penicillin-streptomycin (GIBCO, 15140-122) and 1 µg/ml fungizone (GIBCO, A11138-03). 
MDA-MB-468 were cultured in RPMI 1640 (GIBCO, 31870-025) supplemented with 5% FBS (SIGMA, F7524), 
2 mM L-Glutamine (SIGMA, G7513) and 100 U/ml penicillin-streptomycin (GIBCO, 15140-122). All other 
cells were cultured in RPMI 1640 (GIBCO, 31870-025) supplemented with 10% FBS (SIGMA, F7524), 2 mM 
L-Glutamine (SIGMA, G7513) and 100 U/ml penicillin-streptomycin (GIBCO, 15140-122). Cells were cultured 
for approximately two weeks before assay and discarded after a maximum of two months in culture. The day 
before seeding out cells for the high throughput assay, cells were sub-cultured 1:2. Due to technical reasons, this 
was not performed for biological replicate 2 and 3 of the follow-up secondary screen.
Primary screen - ray designed drug treatment. Cell lines were treated for 48 hours with 19 
small-molecule inhibitors in single and pairwise applications, comprising a total of 171 drug combinations. All 
Fig. 1 Schematic representation of study design. Eight human cancer cell lines from different tissue origins 
were used in this study. Cells were incubated overnight prior to drug addition. In the primary screen, cells were 
screened against 19 small-molecule inhibitors in single and double application, with a total of 171 combinations. 
After 48 hours of drug exposure the assay was terminated, and cell viability was measured using CellTiter-Glo 
2.0 (Promega). In the secondary screen, cells were screened against 7 single small-molecule inhibitors and 6 
combinations for a duration of 48 hours. Drug effect was measured using automated brightfield imaging of 
confluency and CellTiter-Glo 2.0 (Promega).
3Scientific Data |           (2019) 6:237  | https://doi.org/10.1038/s41597-019-0255-7
www.nature.com/scientificdatawww.nature.com/scientificdata/
drugs were pre-diluted in DMSO to a stock concentration of 20 mM. Drugs were applied in an equimolar ray 
design from 10 µM to 0.016 µM using the following procedure: First, 2.0 mM solutions of each inhibitor and 
inhibitor combination were prepared. These were then serially diluted in DMSO (four 5-fold serial dilutions). 
The solutions were further diluted in medium (8 µl inhibitor in DMSO in a total volume of 228 µl), of which 5 µl 
were added to each cell culture well. Total cell culture volume per well was 35 µl. Highest final concentrations were 
thus 10 µM in each well. All dilutions and liquid handling were performed with robotic equipment using sterile 
and pyrogen free pipette tips. The inhibitors are listed in Online-only Table 1. Final DMSO concentration in assay 
wells was 0.5%.
Secondary screen - matrix designed drug treatment. In the secondary screen six combinations were 
screened in a matrix designed across all cell lines. As the PI inhibitor was identified as one of the top drugs 
involved in synergistic combinations, it was chosen as the anchor drug. The inhibitor was combined with BI, 
D1, JN, G2, PD, and 5Z. Cell lines were treated for 48 hours with the seven small-molecule inhibitors in single 
application and six drug combinations in all possible combinations of doses 10, 2, 0.4, 0.08 and 0.02 µM. Drugs, 
prepared as stocks of 20 mM in DMSO, were first diluted to 400x final concentration in DMSO. The solutions 
were further manually mixed 1:1 with either DMSO, for single drugs, or combination drug and applied to a 96 
well plate. Further liquid handling was performed with robotic equipment. The solutions were diluted in medium 
(28.5x), of which 5 µl was added to each cell culture well leading to a total volume of 35 µl. We note that a new set 
of inhibitors was ordered for this screen.
High-throughput screen. Cells were seeded in 384-well plates (CORNING, 3712) at densities shown in 
Table 1 and allowed to attach overnight, before they were treated with small-molecule inhibitors and incubated 
for another 48 hours. The cell seeding densities were selected such that the cells were in a sub confluent stage at 
the time of drug addition. The variances in doubling time between the cell lines were taken into account and 
seeding densities were adjusted so that cell cultures in wells were either in late log phase or early plateau at the 
end of the incubation period. Cell viability was measured using the commercially available CellTiter-Glo 2.0 
assay (Promega). In the secondary screen confluency was included as an additional readout and monitored by 
brightfield imaging using (SpectraMax i3x MiniMax 300 Imaging Cytometer, 2 views per well). A set of control 
wells with cells treated with 0.5% DMSO was included on all plates. The assay was performed with three biological 
replicates, if not stated otherwise.
For the first two biological replicates of the primary screen, two technical replicates are reported. Two of the 
four technical replicates assayed were excluded due to insufficient mixing of drug dilutions for these replicates. 
For the third biological replicate all four technical replicates assayed are included. For MDA-MB-468 and AGS 
cells, one or two biological replicates were performed, respectively. Some data points for the AGS cell line had to 
be excluded due to erroneous drug addition within the robotic script.
For the first biological replicate in the secondary screen, some technical replicates had to be excluded for the 
SW-620 cell line as too little drug volume was added. For the MDA-MB-468 cell line the first biological replicate 
was excluded due to low cell viability in the control wells. For the first, second and third biological replicate some 
technical replicates had to be excluded due to non-efficient cell attachment caused by an air bubble below the cell 
suspension. Additionally, some wells were excluded in the cell confluency data due to condensation of water on 
the bottom of the plate.
Data processing and representation. Viability data - Primary screen. For each 384-well plate, via-
bility data of treated cells was normalised to the DMSO control cells measured in the same plate. Normalised 
viability data for each biological replicate where processed using “R-script-average-of-biological-replicates.R”. 
The average viability score for each technical replicate as well as the average viability score across the biological 
replicates were calculated and exported as tab-separated values (tsv) files. Standard deviation across biological 
replicates was calculated using “R-script-calculate-mean-STDV.R”. Dose response curves were generated using 
“R-script-sensitivity-of-drugs-across-cell-lines-plot.R” (Fig. 2, and in figshare deposit25: Drug_cell_response.
pdf). Drug combination plots were generated from average viability scores with standard deviations using 
Cell line Tissue of origin
Cells/well  
(384-well plate)
Population 
doubling time (h)
Growth Media during 
drug screening
Term Accession 
Number
Term Source 
REF
A498 kidney cancer 972 66.8 RPMI 1640 10%FBS BTO:0003769 BTO
AGS gastric adenocarcinoma 800 20 HAMS’s F12 5%FBS BTO:0001007 BTO
COLO 205 colorectal cancer 3000 23.8 RPMI 1640 10%FBS BTO:0000179 BTO
DU-145 prostate cancer 2100 32.3 RPMI 1640 10%FBS BTO:0001332 BTO
MDA-MB-468 breast cancer 8100 62 RPMI 1640 5%FBS BTO:0001570 BTO
SF-295 glioblastoma 1050 29.5 RPMI 1640 10%FBS BTO:0004213 BTO
SW-620 colorectal cancer 3750 20.4 RPMI 1640 10%FBS BTO:0000675 BTO
UACC-62 melanoma 945 31.3 RPMI 1640 10%FBS BTO:0004152 BTO
Table 1. Cell lines used in screen. Cell line density and growth media used are indicated. All media were 
supplemented with L-glutamine and penicillin-streptomycin. Population doubling time as annotated by 
provider. Cell lines are identified by BRENDA tissue/enzyme source (BTO, Version: 2016-05-05).
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“R-script-plotting-drug-combination.R” (figshare deposit25: Combination_plots_primary_screen.pdf). Data 
points with missing values (14%) are represented as NA values.
Viability and confluency data - Secondary screen. For confluency data brightfield images were analysed using 
the SoftMax® Pro Software field analysis setting. For this, the region of the image covering the well was selected 
and confluency was reported. We note that the absolute values for confluency for very flat and long cells (e.g. 
A498, SF-295) may be underestimated while absolute confluency for round cells (e.g. MDA-MB-498) may be 
overestimated. We further want to indicate that COLO 205 are growing sub-confluent. For completeness of the 
data set, confluency is reported for this cell line. For each 384-well plate, viability and confluency data of treated 
cells was normalised to the plate-internal DMSO control. Technical replicates and averages of biological replicates 
are reported as comma-separated files (csv). These were further processed using “Biological_Average_secondary_
screen.R” to calculate the biological average, standard deviation and coefficient of variation. Drug combination 
plots were generation from average viability scores with standard deviations using “Combination_plots_second-
ary_screen.R” (figshare deposit25: Combination_plots_secondary_screen_viability.pdf). The same script was 
used to generate drug combination plots for confluency data (figshare deposit25: Combination_plots_second-
ary_screen_confluency.pdf).
Calculation of synergy and statistical significance of quantified synergy. Bliss excess was evaluated for all doses 
and biological replicates per drug combination and cell line. We first computed all possible Bliss expectations of 
the reported technical replicates per dose per drug combination. Each technical replicate of combination dose 
responses was then compared to the average of computed Bliss expectations per technical replicate per dose in 
same biological replicate. For calculation of Bliss viability values were capped at one.
+ − ∗Bliss excess viability drug A drug B viability drug B viability drug A: ( ) ( ) ( )
In the primary screen statistical significance of the synergistic response was evaluated. For this the com-
puted Bliss excesses for each drug combination-cell line was compared to a zero-centred normal distribution. 
T-tests were performed to test for statistically significant deviations from a zero-centred distribution. When the 
null hypothesis was rejected the alternative hypothesis was accepted, which states that the distribution is not 
zero-centred, i.e. either antagonistic or synergistic. A conservative Bonferroni correction was done to adjust p 
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Fig. 2 Single dose response data of 4 out of 19 tested drugs across eight cell lines. The plot shows the viability 
of the eight tested cancer cell lines exposed to four different inhibitors in single application in a 5-fold dilution 
series from 10–0.016 µM, with standard deviation indicated by error bars. Viability was normalised to DMSO 
control. Abbreviations: PD-0325901 (PD); Ruxolitinib (RU); PI-103 (PI); SB-505125 (SB).
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values for multiple hypotheses. Combinations with average Bliss excess values ≤ −0.08 and p-value ≤ 0.05 were 
classified as synergies. Bliss excess and significance classifications were performed using “p_values_Bliss.R”. A 
synergy score heatmap and volcano plot visualising mean Bliss excess was generated using “R-script-heatmap.R” 
(Fig. 3a,b). For the secondary screen average Bliss excesses per dose, combination and cell line were computed 
using “Bliss_synergy_secondary_screen.R”. A cumulative Bliss score was calculated using the same script by tak-
ing the mean over the computed Bliss excesses per dose. Combinations with average Bliss excess value < 0 were 
considered as synergies. The lower cut-off was motivated by the fact that five times more combination concentra-
tions were tested in the secondary compared to the primary screen. Example plots of mean Bliss excess ± standard 
deviation for two combination tested in the secondary screen are illustrated in Fig. 3c.
Drug target annotation. Online-only Table 1 lists inhibitor abbreviation, name and unique identifi-
ers (InChiKey and PubChem CID) along with the provider and primary targets as given by provider. CHEBI 
IDs are provided when available. We provide extensive target profile information in the form of bioassay infor-
mation extracted from PubChem (last accessed on 24-06-2019) and kinase profiling data from the MRC PPU 
International Centre for Kinase Profiling - Kinase Profiling Inhibitor Database (http://www.kinase-screen.mrc.
ac.uk/kinase-inhibitors, last time accessed 24-06-2019) available in our figshare deposit25.
For the inhibitors SF1670, BI605906 and 10058-F4 no bioassay information supporting targets given by the 
provider were found in PubChem or MRC PPU Inhibitor Database (proteins inhibited below 10% activity). For 
these inhibitors, we performed an exhaustive literature search to provide annotated information25.
Data records
All data is available at figshare25, https://doi.org/10.6084/m9.figshare.9810719. Below, the file names for the dif-
ferent data sets are listed.
Viability and confluency data. The raw luminescence data from the three biological replicates from the 
primary screen can be found in NTNU_HTS_Repl[1-3]_raw.txt within figshare25. Relative viability data per bio-
logical replicate is available in [Cell line].NTNU_HTS_Repl[1-3]_processed.tsv25. Mean viability data of techni-
cal and biological replicates are depicted in [Cell line].tech-mean_Effect.tsv25 and [Cell line].mean_Effect.tsv25. 
Example plots for drug sensitivity across the eight cell lines are shown in Fig. 2, while all plots can be found in 
Drug_cell_response.pdf25. In Fig. 4, the combination effect of selected drug combinations is visualised. Visualised 
drug combinations are based on significance and strength of synergy (see section for Calculation of synergy and 
statistical significance of quantified synergy, Fig. 3). Figure 4b shows average viability of SF-295 cells and A498 cells 
treated with Doramapimod (BI) in combination with PI-103 (PI), and SF-295 cells treated with BI-D1870 (D1) in 
combination with PI from the primary and secondary screen. The complete file with all drug combination plots 
can be found in Combination_plots_primary_screen.pdf25 for the primary screen and in Combination_plots_
secondary_screen_viability.pdf and Combination_plots_secondary_screen_confluency.pdf for the secondary 
screen for viability and confluency response, respectively25.
The raw luminescence data and relative viability data from the three biological replicates from the secondary 
screen can be found in NTNU_HTS_secondary_viability_REPL[1-3].csv25. Raw as well as relative confluency 
data can be found in NTNU_HTS_secondary_confluency_REPL[1-3].csv25. Mean viability and confluency across 
the three biological replicates are depicted in NTNU_HTS_secondary_viability_Biological_Average.tsv25 and 
NTNU_HTS_secondary_confluency_Biological_Average.tsv25, respectively.
Synergy data. The Bliss excess values for each combination tested in the primary screen across the eight cell 
lines are represented in bliss_significance.tsv25. Synergistic drug combinations are further presented in bliss_syn-
ergies.tsv25. A visual representation of Bliss excess is depicted in Fig. 3a. Cell lines were clustered according to 
Euclidean distances of quantified synergy strengths. 4% synergies were recorded according Bliss Independence 
model.
Bliss excess values for each combination per dose tested in the secondary across eight cell lines are represented 
in bliss_synergies_secondary_screen_viability.tsv25 and bliss_synergies_secondary_screen_confluency.tsv25 from 
viability and confluency data, respectively. A visual representation of Bliss excess ± standard deviation from the 
viability data is shown in bliss_synergies_secondary_screen_plots_viability.pdf25 and in bliss_synergies_second-
ary_screen_plots_confluency.pdf25 from the confluency data. Cumulative bliss scores for the viability data can be 
found in Mean.Bliss.excess.matrix.tsv25.
Technical Validation
Cell line identity. The seven NCI-cell lines used were received from the NCI-DCTD Repository and cul-
tivated no more than 25 passages after reception in the lab. All cell lines were validated by STR profiling per-
formed by Cell Line Authentication Service at ATCC. Eight core STR loci (TH01, D5S818, D13S317, D7S820, 
D16S539, CSF1PO, vWA and TPOX) plus amelogenin were matched to database profiles obtained from ATCC 
and Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ). For two of the cell lines, 
SF-295 and UACC-62, no database profile was available for comparison from ATCC and DSMZ. However, both 
cell lines were found to match their STR profile listed on the ExPASy website (https://web.expasy.org/cellosaurus). 
All 7 cell lines were found to be identical or similar to their database profiles with percent matches at 95–100%. 
The AGS cell line was validated by STR profiling performed by the in-house Genomics Core Facility. Eight core 
STR loci (TH01, D5S818, D13S317, D7S820, D16S539, CSF1PO, vWA and TPOX) plus amelogenin had a match 
of 81% to the ATCC profile (CRL-1739).
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Viability assay performance and variation. The performance of the viability assays was monitored using 
a sample set of small molecule positive controls. In the ray design nine concentrations of digitonin ranging from 
100 µg/ml to 0.02 µg/ml was included in each biological replicate. In the matrix design a sample set with three 
concentrations of the positive controls digitonin, ranging from 26 µg/ml to 3 µg/ml, and staurosporine, rang-
ing from 1.6 µM to 0.18 µM, were included in each plate. The standard deviation of the plate internal reference 
groups was also monitored and was less than 10% at maximum (on average below 5%) in the ray designed screen. 
Overall, we observed a mean coefficient of variation of 8% across all biological replicates in the primary screen 
and 7% in the secondary screen for both the viability and confluency data.
To assess reproducibility between biological replicates, we calculated Pearson correlation coefficients for all 
measured data points (normalised). We observe a high correlation between all comparisons with a correlation 
of R = 0.89 between Replicate 1 vs Replicate 2, R = 0.88 between Replicate 1 vs Replicate 3 and R = 0.87 between 
Replicate 2 vs Replicate 3 of the primary screen (See Fig. 5a–c). In the viability data of the secondary screen we 
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Fig. 3 Overview of synergy scores of all drug combinations across all tested cell lines. (a) The heatmap shows 
Bliss excess across the eight cell lines tested in this study, where a negative value indicates a stronger synergy. 
Bliss excess ≤ −0.11 are coloured in blue (synergy), while values ≥ 0.11 are coloured in red (antagonism). Cell 
lines are clustered using Euclidian distances of synergy strengths, while rows are sorted according to mean Bliss 
excess across all cell lines. (b) Volcano plot showing synergy strength (Bliss excess) vs significance scores of 
synergistic responses. (c) Average Bliss excess ± standard deviation for SF-295 cells treated with Doramapimod 
(BI) in combination with PI-103 (PI) and BI-D1870 (D1) in combination with PI from secondary screen.
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observed a correlation of R = 0.98 between Replicate 1 vs Replicate 2, R = 0.97 between Replicate 1 vs Replicate 
3, and R = 0.98 between Replicate 2 vs Replicate 3. In the confluency data of the secondary screen we observed 
a correlation of R = 0.90 between Replicate 1 vs Replicate 2, R = 0.88 between Replicate 1 vs Replicate 3, and 
0.95
Fig. 4 Example drug combination plots for drug combinations found to be highly synergistic according to 
Bliss excess and p-value. (a) The graphs show viability data with standard deviation for COLO 205 cells tested 
Doramapimod (BI) and Akt Inhibitor VIII (AK) and UACC-62 cells tested with BI-D1870 (D1) and SF1670 
(SF) in the primary screen. (b) The graphs show viability data with standard deviation for SF-295 cells treated 
with drug combinations Doramapimod (BI) - PI-103 (PI) and BI-D1870 (D1) - PI, and A498 cells treated with 
BI - PI in the primary and secondary screen. The data is normalised to DMSO control.
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R = 0.95 between Replicate 2 vs Replicate 3. The average viability of shared data points between the primary and 
secondary screen showed a correlation of R = 0.92 (Fig. 5d). This variation is within the expected variation in high 
throughput cellular viability assays11,26.
Synergistic combinations in primary screen. The primary screen led to the identification of 55 syner-
gies according to the chosen cut-off from 1368 total combinations for all cell lines. An analysis of the list showed 
that 23 unique combinations were classified as synergistic across seven unique cell lines, with no synergistic 
combination in the MDA-MB-468 cell line. The inhibitors PI (targets PIK3CA/B/D, mTOR and DNA-PK) and 
SF (target PTEN) were identified to be involved in the majority of synergistic combination. The PI inhibitor was 
identified as synergistic with BI (target MAPK14) and with D1 (target RPS6KA1/2/3/6) in more than half of the 
tested cell lines. Further synergistic drug pairs sorted by occurrence across cell lines are G2 (target PDPK1), JN 
(targets MAPK8/9/10), P5 (target SYK) and AK (targets AKT1, AKT2, AKT3).
Synergistic combinations in secondary screen. As the PI inhibitor was identified as one of the top 
drugs involved in synergistic combinations, it was chosen as the anchor drug for the secondary screen. We com-
bined the PI inhibitor with the top four synergistic drug pairs judged by occurrence across cell lines. We also 
included PI in combination with PD (targets MAP2K1/2), to investigate synergistic behaviour of drug concentra-
tions outside the concentration ratios tested in the primary screen. This was motivated by the fact that drugs tar-
geting PI3K and MAP2K1/2 have been previously reported to be synergistic in several cell lines18,19. Additionally, 
we tested PI in combination with 5Z a combination previously identified as synergistic in the AGS cell line in a 
previous study by our group15 and Morris et al.16.
Fig. 5 Scatter plots and computed Pearson correlation values for biological replicates. (a) 1 vs 2, (b) 1 vs 3 and 
(c) 2 vs 3. The correlation between shared conditions of primary and secondary screen are shown in (d).
9Scientific Data |           (2019) 6:237  | https://doi.org/10.1038/s41597-019-0255-7
www.nature.com/scientificdatawww.nature.com/scientificdata/
Results from the secondary screen confirmed combinations as being synergistic or antagonistic in most cell 
lines. We confirmed the synergistic effect of PI-G2 in SF-295, SW-620 and UACC-62 cells. Additionally, we 
observed a synergistic response in A498 and AGS cells in the secondary screen. The combination PI-BI was also 
redetected as synergistic in five of the cell lines, while for two cell lines the combination did not show a greater 
effect compared to single drug treatment in the secondary screen. For two combinations, that were not classified 
as synergistic in the primary screen, PI-5Z and PI-PD, we could observe synergistic responses in the secondary 
matrix design screen. The PI-5Z combination was synergistic in two cell lines including AGS cells, confirming 
previous findings15,16. The PI-PD combination (targets PIK3CA/B/D, mTOR and DNA-PK - MAP2K1/2) was 
found to be synergistic in five cell lines and non-synergistic in three cell lines including the two colorectal cancer 
cell lines SW-620 and COLO 205. While colorectal cancer cell lines have been frequently observed to display syn-
ergistic response to combined inhibition of MAP2K1/2 (MEK1/2) and PI3K27–30, weaker synergy has previously 
been observed in SW-620 and COLO 205 cells28.
Usage Notes
Other users may investigate alternative methods for synergy quantification or another threshold using the pro-
vided data. To assist other researchers in visualising and analysing the dataset from the primary screen described 
herein we have prepared files that can be uploaded to the web-service CImbinator (http://rbbt.bsc.es/CImbinator/
CombinationIndex) from which several synergy metrics can be computed and visualised31.
Code availability
The data was processed using R 3.5.2 and RStudio Version 1.1.463. The following packages were used for 
data processing “tidyr” (0.8.3), “dplyr” (0.8.1), “ggrepel” (0.8.1) and “stats” (3.5.2); and data visualization 
“RColorBrewer” (1.1-2), “gplots” (3.0.1.1), “ggplot2” (3.2.0), “ComplexHeatmap”32 (1.20.0), “ggpubr” (0.2) and 
“gridExtra” (2.3).
All code applied for processing and visualising the data is provided at the figshare deposit25.
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